Results 111 to 120 of about 18,827 (200)

Palbociclib in hormone-receptor–positive advanced breast cancer

, 2015
Background Growth of hormone-receptor–positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle.
M Koehler (13283067), S Loibl (9551132), C Giorgetti (13673296), H Iwata (13673290), J Ro (13673284), C Huang Bartlett (13673293), S Verma (7814303), S Loi (9551135), N Harbeck (2561623), S Randolph (13673299), M Cristofanilli (11090790), K Zhang (682253), NC Turner (14537897), F André (13673287)   +13 more
core  

Abstract 2053: Mechanisms of resistance to palbociclib and aromatase inhibitors in hormone receptor positive breast cancer

, 2017
Estrogen receptor-positive (HR+) breast cancer is the most common form of breast cancer that is accountable for the majority of breast cancer mortality.
Saranya Chumsri, Antony Sare, Angela Brodie, Armina A. Kazi   +3 more
core   +1 more source

TMEM45A enhances palbociclib resistance and cellular glycolysis by activating AKT/mTOR signaling pathway in HR+ breast cancer

Cell Death Discovery
Palbociclib, a CDK4/6 inhibitor, plays a crucial role in the treatment of HR+ breast cancer. However, resistance to palbociclib is a significant concern that merits further investigation.
Cui Chen, Zehong Chen, Jinze Zhao, Xinyun Wen, Hanming Yao, Zijin Weng, Huiping Xiong, Zongheng Zheng, Juekun Wu   +8 more
doaj   +1 more source

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors

Pharmaceutics
Background/Objectives: Palbociclib, an oral CDK 4/6 inhibitor, was evaluated in a Pediatric Brain Tumor Consortium (PBTC) phase 1 (NCT02255461; PBTC-042) study to treat children and young adults with recurrent, progressive, or refractory brain tumors ...
John C. Panetta, Nicholas S. Selvo, David Van Mater, Clinton F. Stewart   +3 more
doaj   +1 more source

Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer

Breast Cancer Research
Background Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ESR1) activating mutations, as well as by ER-independent signaling pathways.
Muriel Lainé, Marianne E Greene, Justyna D Kurleto, Grazyna Bozek, Tiffany Leng, Rosemary J Huggins, Barry S Komm, Geoffrey L Greene   +7 more
doaj   +1 more source

Abstract P4-12-08: Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis

, 2018
Introduction The addition of palbociclib to letrozole improves progression free survival (PFS) and response rates compared to letrozole alone in the 1st line treatment of hormone receptor positive advanced breast cancer.
J Helou, J Raphael, DM Naimark
core   +1 more source

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer

Cancer Medicine
Introduction Cyclin‐dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy are the current standard of care for first‐line (1L) treatment of hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR ...
Adam M. Brufsky, Rickard Sandin, Stella Stergiopoulos, Connie Chen, Siddharth Karanth, Benjamin Li, Elizabeth Esterberg, Doris Makari, Sean D. Candrilli, Ravi K. Goyal, Hope S. Rugo   +10 more
doaj   +1 more source

Effects of palbociclib in oral squamous cell carcinoma and the role of PIK3CA in conferring resistance

, 2019
Objective: Lack of effective therapies remains a problem in the treatment of oral squamous cell carcinoma (OSCC), especially in patients with advanced tumors.
Chin, Iuan Sheau, Zainal, Nur Syafinaz, Yee, Pei San, Rahman, Zainal Ariff Abdul, Gan, Chai Phei, Patel, Vyomesh, Gutkind, J. Silvio, Wong, Zheng Wei, Lee, Bernard Kok Bang, Mun, Kein Seong, Cheong, Sok Ching   +10 more
core  

Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth

, 2019
Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge ...
Cheng-Lung Hsu, Angel Chao, Chyong-Huey Lai, Li-Yu Lee, Chia-Lung Tsai, Tzu-Hao Wang, Chiao-Yun Lin   +6 more
core   +1 more source

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer [PDF]

, 2018
BACKGROUND The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2 ...
Verma, S., Harbeck, N., Loi, S., André, F., Ro, J., Turner, N.C., Huang, X., Huang Bartlett, C., Masuda, N., Iwata, H., Slamon, D.J., Giorgetti, C., Cristofanilli, M., Bondarenko, I., Colleoni, M., Puyana Theall, K., Loibl, S., Im, S.-A., DeMichele, A.   +18 more
core